XML 24 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Operating Activities      
Net income (loss) $ 63,087 $ 114,205 $ (193,420)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities      
Depreciation 183 2,763 757
Amortization of premium and discounts on investment securities 0 140 595
Non-cash charge on acquired in-process research and development 5,619 0 0
Non-cash gain on extinguishment of royalty purchase agreement (125,000) 0 0
Deferred income taxes 0 (3,366) 22,954
Share-based compensation 11,072 18,171 31,660
Changes in operating assets and liabilities:      
Income tax receivable 1,387 (1,387) 3,421
Due from Novartis Pharma AG 0 3,531 858
Prepaid expense and other current assets 1,060 (68) (995)
Accrued interest receivable 0 466 203
Other assets 10 438 27
Accrued research and development expenses 2,353 (42,256) 28,420
Accounts payable and accrued expenses (1,682) (4,481) 14
Deferred revenue 0 (209,977) (3,090)
Net cash used in operating activities (41,911) (121,821) (108,596)
Investing Activities      
Purchase of marketable securities 0 (12,014) (72,197)
Maturities of marketable securities 0 166,806 86,500
Purchase of property and equipment 0 0 (572)
Net cash provided by investing activities 0 154,792 13,731
Financing Activities      
Proceeds from issuance of common stock related to acquisition 6,075 0 0
Proceeds from employee stock plan purchases and stock option exercises 65 71 6,934
Net cash provided by financing activities 6,140 71 6,934
Net change in cash and cash equivalents (35,771) 33,042 (87,931)
Cash and cash equivalents      
Beginning of period 166,972 133,930 221,861
End of period 131,201 166,972 133,930
Supplemental disclosure of cash paid      
Income taxes received, net (2,467) (245) (26,998)
Supplemental disclosures of non-cash information related to investing activities      
Change in unrealized gain (loss) on available for sale securities, net of tax 0 212 261
Common stock issued to acquire net assets of Inception 4, Inc. $ 11,694 $ 0 $ 0